Creative Medical Technology
CELZ
14 hedge funds and large institutions have $1.13M invested in Creative Medical Technology in 2022 Q2 according to their latest regulatory filings, with 5 funds opening new positions, 4 increasing their positions, 1 reducing their positions, and 5 closing their positions.
300% more repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 1
54% more capital invested
Capital invested by funds: $735K → $1.13M (+$397K)
2.09% more ownership
Funds ownership: 0.3% → 2.38% (+2.1%)
0% more funds holding
Funds holding: 14 → 14 (0)
0% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$2.01M |
| 2 |
BFM
Boothbay Fund Management
New York
|
+$143K |
| 3 |
Vanguard Group
Malvern,
Pennsylvania
|
+$57.8K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
+$55.4K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$16.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCA
Sassicaia Capital Advisers
Jericho,
New York
|
-$122K |
| 2 |
SSA
Schonfeld Strategic Advisors
New York
|
-$84K |
| 3 |
XT
XTX Topco
George Town,
Cayman Islands
|
-$68K |
| 4 |
TSS
Two Sigma Securities
New York
|
-$52K |
| 5 |
UBS Group
Zurich,
Switzerland
|
-$36K |
CELZ Hedge Fund Activity: Q2 2022 in Review
14 of the 5,958 institutional investors tracked by Wall St. Rank reported a position in Creative Medical Technology (CELZ) for Q2 2022, worth a combined $1.13M — up 54% from $735K a quarter earlier.
Fund positioning in CELZ was balanced in Q2 2022: 5 funds opened new positions, 5 closed out, 4 added to existing stakes and 1 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $2.01M. The largest seller was Sassicaia Capital Advisers, exiting entirely with an estimated $122K sold.
- 14 institutional investors held Creative Medical Technology (CELZ) as of Q2 2022, unchanged from Q1 2022.
- Funds reported $1.13M of Creative Medical Technology stock for Q2 2022, up 54% quarter-over-quarter.
- 5 funds opened new Creative Medical Technology positions in Q2 2022 and 5 closed out, a net change of 0 holders.
- The largest Creative Medical Technology buyer in Q2 2022 was Armistice Capital, an estimated $2.01M added.
- The largest Creative Medical Technology seller in Q2 2022 was Sassicaia Capital Advisers, an estimated $122K sold.
Based on aggregated 13F filings for Q2 2022.